Literature DB >> 24791942

An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.

Stephanie C Casey1, Yulin Li, Dean W Felsher.   

Abstract

Tumors are genetically complex and can have a multitude of mutations. Consequently, it is surprising that the suppression of a single oncogene can result in rapid and sustained tumor regression, illustrating the concept that cancers are often "oncogene addicted." The mechanism of oncogene addiction has been presumed to be largely cell autonomous as a consequence of the restoration of normal physiological programs that induce proliferative arrest, apoptosis, differentiation, and/or cellular senescence. Interestingly, it has recently become apparent that upon oncogene inactivation, the immune response is critical in mediating the phenotypic consequences of oncogene addiction. In particular, CD4(+) T cells have been suggested to be essential to the remodeling of the tumor microenvironment, including the shutdown of host angiogenesis and the induction of cellular senescence in the tumor. However, adaptive and innate immune cells are likely involved. Thus, the effectors of the immune system are involved not only in tumor initiation, tumor progression, and immunosurveillance, but also in the mechanism of tumor regression upon targeted oncogene inactivation. Hence, oncogene inactivation may be an effective therapeutic approach because it both reverses the neoplastic state within a cancer cell and reactivates the host immune response that remodels the tumor microenvironment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24791942      PMCID: PMC4201505          DOI: 10.1007/s12026-014-8503-6

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  144 in total

Review 1.  Translating p53 into the clinic.

Authors:  Chit Fang Cheok; Chandra S Verma; José Baselga; David P Lane
Journal:  Nat Rev Clin Oncol       Date:  2010-10-26       Impact factor: 66.675

2.  Immune deficiency and risk for malignancy among persons with AIDS.

Authors:  Sam M Mbulaiteye; Robert J Biggar; James J Goedert; Eric A Engels
Journal:  J Acquir Immune Defic Syndr       Date:  2003-04-15       Impact factor: 3.731

Review 3.  The tumour microenvironment as a target for chemoprevention.

Authors:  Adriana Albini; Michael B Sporn
Journal:  Nat Rev Cancer       Date:  2007-02       Impact factor: 60.716

4.  Elevated risk of lung cancer among people with AIDS.

Authors:  Anil K Chaturvedi; Ruth M Pfeiffer; Leonard Chang; James J Goedert; Robert J Biggar; Eric A Engels
Journal:  AIDS       Date:  2007-01-11       Impact factor: 4.177

5.  NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma.

Authors:  Stephen R Mattarollo; Alison C West; Kim Steegh; Helene Duret; Christophe Paget; Ben Martin; Geoffrey M Matthews; Jake Shortt; Marta Chesi; P Leif Bergsagel; Michael Bots; Johannes Zuber; Scott W Lowe; Ricky W Johnstone; Mark J Smyth
Journal:  Blood       Date:  2012-08-28       Impact factor: 22.113

6.  Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma.

Authors:  Antonia Busse; Anne Marie Asemissen; Anika Nonnenmacher; Floriane Braun; Sebastian Ochsenreither; David Stather; Alberto Fusi; Alexander Schmittel; Kurt Miller; Eckhard Thiel; Ulrich Keilholz
Journal:  Eur J Cancer       Date:  2011-01-05       Impact factor: 9.162

Review 7.  AIDS-related malignancies.

Authors:  Chris Boshoff; Robin Weiss
Journal:  Nat Rev Cancer       Date:  2002-05       Impact factor: 60.716

8.  Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells.

Authors:  Claudia Wrzesinski; Chrystal M Paulos; Andrew Kaiser; Pawel Muranski; Douglas C Palmer; Luca Gattinoni; Zhiya Yu; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Immunother       Date:  2010-01       Impact factor: 4.456

Review 9.  Reversing cancer from inside and out: oncogene addiction, cellular senescence, and the angiogenic switch.

Authors:  Dean W Felsher
Journal:  Lymphat Res Biol       Date:  2008       Impact factor: 2.589

10.  Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors.

Authors:  Kwan-Hyuck Baek; Dongha Bhang; Alexander Zaslavsky; Liang-Chuan Wang; Anil Vachani; Carla F Kim; Steven M Albelda; Gerard I Evan; Sandra Ryeom
Journal:  J Clin Invest       Date:  2013-09-09       Impact factor: 14.808

View more
  6 in total

Review 1.  The MYC oncogene is a global regulator of the immune response.

Authors:  Stephanie C Casey; Virginie Baylot; Dean W Felsher
Journal:  Blood       Date:  2018-03-07       Impact factor: 22.113

2.  A new therapeutic potential for cancers: One CAR with 2 different engines!

Authors:  Abdolkarim Sheikhi; Abdollah Jafarzadeh
Journal:  Hum Vaccin Immunother       Date:  2017-05-11       Impact factor: 3.452

Review 3.  MYC: Master Regulator of Immune Privilege.

Authors:  Stephanie C Casey; Virginie Baylot; Dean W Felsher
Journal:  Trends Immunol       Date:  2017-02-21       Impact factor: 16.687

4.  A pan-cancer modular regulatory network analysis to identify common and cancer-specific network components.

Authors:  Sara A Knaack; Alireza Fotuhi Siahpirani; Sushmita Roy
Journal:  Cancer Inform       Date:  2014-10-28

5.  Purification, characterization, and antitumor activity of a novel glucan from the fruiting bodies of Coriolus Versicolor.

Authors:  Annoor Awadasseid; Jie Hou; Yaser Gamallat; Shang Xueqi; Kuugbee D Eugene; Ahmed Musa Hago; Djibril Bamba; Abdo Meyiah; Chiwala Gift; Yi Xin
Journal:  PLoS One       Date:  2017-02-08       Impact factor: 3.240

Review 6.  Mutation or not, what directly establishes a neoplastic state, namely cellular immortality and autonomy, still remains unknown and should be prioritized in our research.

Authors:  Shengming Zhu; Jiangang Wang; Lucas Zellmer; Ningzhi Xu; Mei Liu; Yun Hu; Hong Ma; Fei Deng; Wenxiu Yang; Dezhong Joshua Liao
Journal:  J Cancer       Date:  2022-07-04       Impact factor: 4.478

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.